Changes in Treatment After Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography in Patients With Prostate Cancer: A Retrospective Case Series Study
Purpose The use of gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography (Ga-68 PSMA-11 PET/CT) is becoming increasingly common among men with prostate cancer (PCa). However, it remains uncertain which patients will derive the most benefit, and there is a...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Urological Oncology Society
2024-07-01
|
| Series: | Journal of Urologic Oncology |
| Subjects: | |
| Online Access: | http://www.e-juo.org/upload/pdf/juo-244800380019.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846143086220017664 |
|---|---|
| author | Si Hyun Kim Chang Wook Jeong Minh-Tung Do Jang Hee Han Seung-Hwan Jeong Hyeong Dong Yuk Ja Hyeon Ku Hyeon Hoe Kim Gi Jeong Cheon Cheol Kwak |
| author_facet | Si Hyun Kim Chang Wook Jeong Minh-Tung Do Jang Hee Han Seung-Hwan Jeong Hyeong Dong Yuk Ja Hyeon Ku Hyeon Hoe Kim Gi Jeong Cheon Cheol Kwak |
| author_sort | Si Hyun Kim |
| collection | DOAJ |
| description | Purpose The use of gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography (Ga-68 PSMA-11 PET/CT) is becoming increasingly common among men with prostate cancer (PCa). However, it remains uncertain which patients will derive the most benefit, and there is a scarcity of real-world data regarding its impact on altering treatment plans. This study investigated which patients would most benefit from Ga-68 PSMA-11 PET/CT, focusing on detection rates and changes in treatment strategies, drawing from a single-center experience. Materials and Methods In total, 230 men with PCa who underwent Ga-68 PSMA-11 PET/CT between November 2021 and August 2022 were included in this retrospective study. The patients were classified into 5 groups based on their disease status: group 1, further work-up for high-risk localized PCa; group 2, de novo metastatic PCa; group 3, biochemical recurrence after definitive treatment; group 4, castration-resistant PCa; group 5, others. The positivity rate, positive lesions, predictive value of lymph node metastases, comparison with conventional images, and treatment changes after Ga-68 PSMA-11 PET/CT were analyzed in each group. Results Of the 230 patients, 40 (17.4%), 20 (8.7%), 77 (33.5%), 76 (33.0%), and 17 (7.4%) were classified into groups 1–5, respectively. Ga-68 PSMA-11 PET/CT showed lesions in 74.8% of patients, and the optimal cutoff value for PSA was 1.99 ng/mL. Lesions not observed on conventional imaging were found in 62 patients (33.2%). In 38 patients (13.5%), treatment was changed due to Ga-68 PSMA-11 PET/CT. Conclusions These real-world data suggest that Ga-68 PSMA-11 PET/CT may be clinically useful for various disease conditions, as substantial stage migration and subsequent treatment changes occur in men with PCa. However, the prognostic impact of this modality remains unclear; thus, a well-designed prospective study is needed to address this issue. |
| format | Article |
| id | doaj-art-ac1bc9a5d5ee4b7a8c9d5054c5ccb796 |
| institution | Kabale University |
| issn | 2951-603X 2982-7043 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Korean Urological Oncology Society |
| record_format | Article |
| series | Journal of Urologic Oncology |
| spelling | doaj-art-ac1bc9a5d5ee4b7a8c9d5054c5ccb7962024-12-03T04:18:43ZengKorean Urological Oncology SocietyJournal of Urologic Oncology2951-603X2982-70432024-07-0122215716510.22465/juo.244800380019585Changes in Treatment After Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography in Patients With Prostate Cancer: A Retrospective Case Series StudySi Hyun Kim0Chang Wook Jeong1Minh-Tung Do2Jang Hee Han3Seung-Hwan Jeong4Hyeong Dong Yuk5Ja Hyeon Ku6Hyeon Hoe Kim7Gi Jeong Cheon8Cheol Kwak9 Department of Urology, Seoul National University Hospital, Seoul, Korea Department of Urology, Seoul National University Hospital, Seoul, Korea Department of Urology, Seoul National University Hospital, Seoul, Korea Department of Urology, Seoul National University Hospital, Seoul, Korea Department of Urology, Seoul National University Hospital, Seoul, Korea Department of Urology, Seoul National University Hospital, Seoul, Korea Department of Urology, Seoul National University Hospital, Seoul, Korea Department of Urology, Seoul National University Hospital, Seoul, Korea Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea Department of Urology, Seoul National University Hospital, Seoul, KoreaPurpose The use of gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography (Ga-68 PSMA-11 PET/CT) is becoming increasingly common among men with prostate cancer (PCa). However, it remains uncertain which patients will derive the most benefit, and there is a scarcity of real-world data regarding its impact on altering treatment plans. This study investigated which patients would most benefit from Ga-68 PSMA-11 PET/CT, focusing on detection rates and changes in treatment strategies, drawing from a single-center experience. Materials and Methods In total, 230 men with PCa who underwent Ga-68 PSMA-11 PET/CT between November 2021 and August 2022 were included in this retrospective study. The patients were classified into 5 groups based on their disease status: group 1, further work-up for high-risk localized PCa; group 2, de novo metastatic PCa; group 3, biochemical recurrence after definitive treatment; group 4, castration-resistant PCa; group 5, others. The positivity rate, positive lesions, predictive value of lymph node metastases, comparison with conventional images, and treatment changes after Ga-68 PSMA-11 PET/CT were analyzed in each group. Results Of the 230 patients, 40 (17.4%), 20 (8.7%), 77 (33.5%), 76 (33.0%), and 17 (7.4%) were classified into groups 1–5, respectively. Ga-68 PSMA-11 PET/CT showed lesions in 74.8% of patients, and the optimal cutoff value for PSA was 1.99 ng/mL. Lesions not observed on conventional imaging were found in 62 patients (33.2%). In 38 patients (13.5%), treatment was changed due to Ga-68 PSMA-11 PET/CT. Conclusions These real-world data suggest that Ga-68 PSMA-11 PET/CT may be clinically useful for various disease conditions, as substantial stage migration and subsequent treatment changes occur in men with PCa. However, the prognostic impact of this modality remains unclear; thus, a well-designed prospective study is needed to address this issue.http://www.e-juo.org/upload/pdf/juo-244800380019.pdfpositron emission tomographycomputed tomographygallium-68 prostate-specific membrane antigen -11prostatic neoplasmslymph nodecancer staging |
| spellingShingle | Si Hyun Kim Chang Wook Jeong Minh-Tung Do Jang Hee Han Seung-Hwan Jeong Hyeong Dong Yuk Ja Hyeon Ku Hyeon Hoe Kim Gi Jeong Cheon Cheol Kwak Changes in Treatment After Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography in Patients With Prostate Cancer: A Retrospective Case Series Study Journal of Urologic Oncology positron emission tomography computed tomography gallium-68 prostate-specific membrane antigen -11 prostatic neoplasms lymph node cancer staging |
| title | Changes in Treatment After Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography in Patients With Prostate Cancer: A Retrospective Case Series Study |
| title_full | Changes in Treatment After Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography in Patients With Prostate Cancer: A Retrospective Case Series Study |
| title_fullStr | Changes in Treatment After Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography in Patients With Prostate Cancer: A Retrospective Case Series Study |
| title_full_unstemmed | Changes in Treatment After Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography in Patients With Prostate Cancer: A Retrospective Case Series Study |
| title_short | Changes in Treatment After Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography in Patients With Prostate Cancer: A Retrospective Case Series Study |
| title_sort | changes in treatment after gallium 68 prostate specific membrane antigen 11 positron emission tomography computed tomography in patients with prostate cancer a retrospective case series study |
| topic | positron emission tomography computed tomography gallium-68 prostate-specific membrane antigen -11 prostatic neoplasms lymph node cancer staging |
| url | http://www.e-juo.org/upload/pdf/juo-244800380019.pdf |
| work_keys_str_mv | AT sihyunkim changesintreatmentaftergallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyinpatientswithprostatecanceraretrospectivecaseseriesstudy AT changwookjeong changesintreatmentaftergallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyinpatientswithprostatecanceraretrospectivecaseseriesstudy AT minhtungdo changesintreatmentaftergallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyinpatientswithprostatecanceraretrospectivecaseseriesstudy AT jangheehan changesintreatmentaftergallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyinpatientswithprostatecanceraretrospectivecaseseriesstudy AT seunghwanjeong changesintreatmentaftergallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyinpatientswithprostatecanceraretrospectivecaseseriesstudy AT hyeongdongyuk changesintreatmentaftergallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyinpatientswithprostatecanceraretrospectivecaseseriesstudy AT jahyeonku changesintreatmentaftergallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyinpatientswithprostatecanceraretrospectivecaseseriesstudy AT hyeonhoekim changesintreatmentaftergallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyinpatientswithprostatecanceraretrospectivecaseseriesstudy AT gijeongcheon changesintreatmentaftergallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyinpatientswithprostatecanceraretrospectivecaseseriesstudy AT cheolkwak changesintreatmentaftergallium68prostatespecificmembraneantigen11positronemissiontomographycomputedtomographyinpatientswithprostatecanceraretrospectivecaseseriesstudy |